Literature DB >> 26852285

Proteins involved on TGF-β pathway are up-regulated during the acute phase of experimental Chagas disease.

Roberto Rodrigues Ferreira1, Elen Mello de Souza2, Fabiane Loiola de Oliveira1, Patrícia Mello Ferrão1, Leonardo Henrique Ferreira Gomes1, Leila Mendonça-Lima1, Marcelo Meuser-Batista2, Sabine Bailly3, Jean Jacques Feige3, Tania Cremonini de Araujo-Jorge2, Mariana Caldas Waghabi4.   

Abstract

Studies developed by our group in the last years have shown the involvement of TGF-β in acute and chronic Chagas heart disease, with elevated plasma levels and activated TGF-β cell signaling pathway as remarkable features of patients in the advanced stages of this disease, when high levels of cardiac fibrosis is present. Imbalance in synthesis and degradation of extracellular matrix components is the basis of pathological fibrosis and TGF-β is considered as one of the key regulators of this process. In the present study, we investigated the activity of the TGF-β signaling pathway, including receptors and signaling proteins activation in the heart of animals experimentally infected with Trypanosoma cruzi during the period that mimics the acute phase of Chagas disease. We observed that T. cruzi-infected animals presented increased expression of TGF-β receptors. Overexpression of receptors was followed by an increased phosphorylation of Smad2/3, p38 and ERK. Furthermore, we correlated these activities with cellular factors involved in the fibrotic process induced by TGF-β. We observed that the expression of collagen I, fibronectin and CTGF were increased in the heart of infected animals on day 15 post-infection. Correlated with the increased TGF-β activity in the heart, we found that serum levels of total TGF-β were significantly higher during acute infection. Taken together, our data suggest that the commitment of the heart associates with increased activity of TGF-β pathway and expression of its main components. Our results, confirm the importance of this cytokine in the development and maintenance of cardiac damage caused by T. cruzi infection.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Chagas disease; Fibrosis; Infection; TGF-β; Trypanosoma cruzi

Mesh:

Substances:

Year:  2016        PMID: 26852285     DOI: 10.1016/j.imbio.2016.01.009

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  17 in total

Review 1.  Transforming growth factor-β in myocardial disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2022-01-04       Impact factor: 32.419

2.  Resolvin D1 Administration Is Beneficial in Trypanosoma cruzi Infection.

Authors:  Aline L Horta; Tere Williams; Bing Han; Yanfen Ma; Ana Paula J Menezes; Vincent Tu; André Talvani; Louis M Weiss; Huan Huang
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

3.  Alterations to the Cardiac Metabolome Induced by Chronic T. cruzi Infection Relate to the Degree of Cardiac Pathology.

Authors:  Kristyn Hoffman; Zongyuan Liu; Ekram Hossain; Maria Elena Bottazzi; Peter J Hotez; Kathryn M Jones; Laura-Isobel McCall
Journal:  ACS Infect Dis       Date:  2021-04-12       Impact factor: 5.578

4.  Leishmania amazonensis-Induced cAMP Triggered by Adenosine A2B Receptor Is Important to Inhibit Dendritic Cell Activation and Evade Immune Response in Infected Mice.

Authors:  Amanda Braga Figueiredo; Míriam Conceição Souza-Testasicca; Tiago Wilson Patriarca Mineo; Luís Carlos Crocco Afonso
Journal:  Front Immunol       Date:  2017-07-25       Impact factor: 7.561

5.  LncRNAs: Proverbial Genomic "Junk" or Key Epigenetic Regulators During Cardiac Fibrosis in Diabetes?

Authors:  Saumik Biswas; Anu Alice Thomas; Subrata Chakrabarti
Journal:  Front Cardiovasc Med       Date:  2018-04-04

6.  Correlation of transforming growth factor-β1 and tumour necrosis factor levels with left ventricular function in Chagas disease.

Authors:  Eduardo Ov Curvo; Roberto R Ferreira; Fabiana S Madeira; Gabriel F Alves; Mayara C Chambela; Veronica G Mendes; Luiz Henrique C Sangenis; Mariana C Waghabi; Roberto M Saraiva
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-19       Impact factor: 2.743

7.  TGF-β Polymorphisms Are a Risk Factor for Chagas Disease.

Authors:  Roberto Rodrigues Ferreira; Fabiana da Silva Madeira; Gabriel Farias Alves; Mayara da Costa Chambela; Eduardo de Oliveira Vaz Curvo; Aline Dos Santos Moreira; Renata Almeida de Sá; Leila Mendonça-Lima; Pedro Hernan Cabello; Sabine Bailly; Jean-Jacques Feige; Tania Cremonini Araujo-Jorge; Roberto Magalhães Saraiva; Mariana Caldas Waghabi
Journal:  Dis Markers       Date:  2018-02-18       Impact factor: 3.434

8.  TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease.

Authors:  Roberto Rodrigues Ferreira; Rayane da Silva Abreu; Glaucia Vilar-Pereira; Wim Degrave; Marcelo Meuser-Batista; Nilma Valéria Caldeira Ferreira; Otacílio da Cruz Moreira; Natália Lins da Silva Gomes; Elen Mello de Souza; Isalira P Ramos; Sabine Bailly; Jean-Jacques Feige; Joseli Lannes-Vieira; Tania C de Araújo-Jorge; Mariana Caldas Waghabi
Journal:  PLoS Negl Trop Dis       Date:  2019-07-31

9.  Differential Role of TGF-β in Extracellular Matrix Regulation During Trypanosoma cruzi-Host Cell Interaction.

Authors:  Tatiana Araújo Silva; Luis Felipe de Carvalho Ferreira; Mirian Claudia de Souza Pereira; Claudia Magalhães Calvet
Journal:  Int J Mol Sci       Date:  2019-09-29       Impact factor: 5.923

10.  The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries.

Authors:  Goonaseelan Pillai; Kelly Chibale; Edwin C Constable; Akiko N Keller; Marcelo M Gutierrez; Fareed Mirza; Christian Sengstag; Collen Masimirembwa; Paolo Denti; Gary Maartens; Michèle Ramsay; Bernhards Ogutu; Eyasu Makonnen; Richard Gordon; Carlos Gil Ferreira; Fernando Alberto Goldbaum; Wim M S Degrave; Jonathan Spector; Brigitta Tadmor; Hedwig J Kaiser
Journal:  BMC Med Educ       Date:  2018-10-10       Impact factor: 2.463

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.